Full-Time
Associate Scientist II
Research
Posted on 10/24/2024
Vaxcyte
201-500 employees
Develops vaccines for bacterial infections
Compensation Overview
$89k - $102kAnnually
Junior, Mid
San Carlos, CA, USA
This position is onsite in San Carlos, CA.
- BA/BS in Biology, Chemistry, Chemical Engineering, or related discipline with 2 years of industrial experience.
- Experience with Cytiva AKTA chromatography system is a plus.
- Highly organized, strong attention to details and excellent record keeping/documentation abilities.
- Critical thinking and ability to analyze data.
- Eager and able to learn and understand new concepts.
- Execution of laboratory methods for protein expression and purification including cell-free protein expression, affinity, ion exchange, and size exclusion chromatography, SDS-PAGE, UV spectroscopy.
- Execution of laboratory methods for polysaccharide purification including ion exchange chromatography and tangential flow filtration (TFF).
- Preparation of materials needed for routine laboratory practices such as buffers and analytical standards.
- Perform data analysis and present data in team meetings.
- Work within a team environment and provide support to further team projects.
Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to protect vulnerable populations from serious bacterial infections.
Company Stage
IPO
Total Funding
$2.3B
Headquarters
Foster City, California
Founded
2013
6 month growth
↑ 27%1 year growth
↑ 65%2 year growth
↑ 131%
Simplify's Take
What believers are saying
- Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
- The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
- The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.
What critics are saying
- The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
- The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.
What makes Vaxcyte unique
- Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
- Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
- The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.
Help us improve and share your feedback! Did you find this helpful?